Skip navigation

Collect and Analyze Patient Level Data for Successful Registries, RWE Utilization and HEOR Value

January 29-30, 2020
  • Miami, FL

Patient Registries, Real World Evidence (RWE) and Health Economic Outcomes Research (HEOR) are disrupting the future for patients. The advances in patient level data collection and analyses have provided a dramatic improvement in decision making regarding patient treatment. Registry, RWE and HEOR data is being used to further drug development, FDA new drug approval and payer reimbursement. The results are better patient outcomes and an improvement in treatment as well as quality of care.

Topics to Explore in Three Separate Tracks Focusing on Patient Registries, RWE and HEOR:

  • The Future of Registries and Real World Evidence (RWE) — Realizing Mutual Goals for Patients, Payers, Providers and Pharma
  • Understanding and Using Patient-Reported, Real World Evidence from Social Media
  • Leveraging Big Data and Artificial Intelligence (AI) for Registries, RWE Generation and Personalized Decision Making
  • Build Common Data Models Across Multiple Data Sources
  • Learn about emerging opportunities to use RWE for regulatory submissions
  • Engage patients and improve access to RWE and patient registries
  • Collect and analyze patient data with the goal of improving health treatment outcomes
  • Identify best approaches to analyzing HEOR data and economic modeling
  • Examine success factors for creating rare disease registries
  • Involve patient reported outcomes in registry and real world initiatives
  • Inform HEOR strategy for predictive modeling to improve market access and reimbursement strategy

Patient Registries, Real World Evidence and HEOR Summit

Collect and Analyze Patient Level Data for Successful Registries, RWE Utilization and HEOR Value

Patient Registries, Real World Evidence (RWE) and Health Economic Outcomes Research (HEOR) are disrupting the future for patients. The advances in patient level data collection and analyses have provided a dramatic improvement in decision making regarding patient treatment. Registry, RWE and HEOR data is being used to further drug development, FDA new drug approval and payer reimbursement. The results are better patient outcomes and an improvement in treatment as well as quality of care.

Topics to Explore in Three Separate Tracks Focusing on Patient Registries, RWE and HEOR:

  • The Future of Registries and Real World Evidence (RWE) — Realizing Mutual Goals for Patients, Payers, Providers and Pharma
  • Understanding and Using Patient-Reported, Real World Evidence from Social Media
  • Leveraging Big Data and Artificial Intelligence (AI) for Registries, RWE Generation and Personalized Decision Making
  • Build Common Data Models Across Multiple Data Sources
  • Learn about emerging opportunities to use RWE for regulatory submissions
  • Engage patients and improve access to RWE and patient registries
  • Collect and analyze patient data with the goal of improving health treatment outcomes
  • Identify best approaches to analyzing HEOR data and economic modeling
  • Examine success factors for creating rare disease registries
  • Involve patient reported outcomes in registry and real world initiatives
  • Inform HEOR strategy for predictive modeling to improve market access and reimbursement strategy